Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs.
Sustained release asymmetric membrane capsular systems were developed for simultaneous oral delivery of rifampicin and isoniazid sodium in order to reduce the problems associated with the multi drug therapy of tuberculosis. Dense semipermeable membrane coating capsules were also prepared for the delivery of these drugs by adopting two different filling approaches. In vitro release studies were carried out for both types of systems and the results were compared. Asymmetric membrane capsules provided sustained release of rifampicin associated with initial burst release, where isoniazid release rates were comparatively high due to higher aqueous solubility. Dense semipermeable membrane systems provided controlled release of both drugs but were devoid of initial burst release of isoniazid. To overcome these drawbacks, a modified asymmetric system was developed by adding appropriate amount of hydrophilic polymer mixture with isoniazid. The system provided satisfactory sustained release of rifampicin and isoniazid with initial burst release may be sufficient to achieve minimum effective concentration in blood. In vitro dissolution kinetics of the systems followed first order kinetics and statistical analysis of release rate data proved that modified asymmetric system was better amongst the developed systems.
Prabakaran
D
D
Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar MP, 470 003, India.
Singh
Paramjit
P
Jaganathan
K S
KS
Vyas
Suresh P
SP
D000995:Antitubercular Agents / Q000008:administration & dosage*; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D005079:Excipients; D007538:Isoniazid / Q000008:administration & dosage; D007700:Kinetics; D008567:Membranes, Artificial; D008855:Microscopy, Electron, Scanning; D009995:Osmosis; D010539:Permeability; D012293:Rifampin / Q000008:administration & dosage
D000995:Antitubercular Agents; D003692:Delayed-Action Preparations; D005079:Excipients; D008567:Membranes, Artificial; D007538:Isoniazid; D012293:Rifampin